Difference between revisions of "Epoetin alfa (Procrit)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (One intermediate revision by the same user not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
Latest revision as of 01:06, 29 June 2024
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Epoetin alfa (Procrit) patient instructions for use[5][6]
- Brief patient counseling information can be found in the Epoetin alfa (Procrit) package insert[1]
- Epoetin alfa (Procrit) patient drug information (Chemocare)[7]
- Epoetin alfa (Procrit) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 1989-06-01: Initial FDA approval
Also known as
- Generic names: Erythropoetin, Erythropoietin
- Brand names: Ceriton, Dynepo, Epoch, Epofer, Epogen, Epogin, Epoimmun, Epomax, Epopen, Epox, Epoyet, Eprex, Eritrelan, Erypo, Erythrostim, Espo, Globuren, Hemapo, Hemax, LG Espogen, Procrit, Recormon, Vepox, Vintor, Wepox
References
- ↑ 1.0 1.1 1.2 Epoetin alfa (Procrit) package insert
- ↑ Epoetin alfa (Procrit) package insert (locally hosted backup)
- ↑ Procrit manufacturer's website
- ↑ As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Epoetin alfa (Procrit) patient instructions for use
- ↑ Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)
- ↑ Epoetin alfa (Procrit) patient drug information (Chemocare)
- ↑ Epoetin alfa (Procrit) patient drug information (UpToDate)